Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIL_FOLL12 Response-adapted Strategy in Follicular Lymphoma
NCT02063685Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jul 2012
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-Free Survival. Started Jul 2012; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02063685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063685.